Why the study?
Does intracoronary application of a selective deltaPKC inhibitor reduce reperfusion injury in preclinical models of acute myocardial infarction?
Does intracoronary application of a selective deltaPKC inhibitor reduce reperfusion injury in preclinical models of acute myocardial infarction?
Inhibition of deltaPKC at the time of reperfusion protects against ischemia/reperfusion injury in preclinical models of acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Warrants clinical trials of deltaPKC inhibition in AMI reperfusion; leaves open translation of animal benefits to patients.
BACKGROUND: Current treatment for acute myocardial infarction (AMI) focuses on reestablishing blood flow (reperfusion). Paradoxically, reperfusion itself may cause additional injury to the heart. We previously found that delta-protein kinase C (deltaPKC) inhibition during simulated ischemia/reperfusion in isolated rat hearts is cardioprotective. We focus here on the role for deltaPKC during reperfusion only, using an in vivo porcine model of AMI. METHODS AND RESULTS: An intracoronary application of a selective deltaPKC inhibitor to the heart at the time of reperfusion reduced infarct size, improved cardiac function, inhibited troponin T release, and reduced apoptosis. Using 31P NMR in isolated perfused mouse hearts, we found a faster recovery of ATP levels in hearts treated with the deltaPKC inhibitor during reperfusion only. CONCLUSIONS: Reperfusion injury after cardiac ischemia is mediated, at least in part, by deltaPKC activation. This study suggests that including a deltaPKC inhibitor at reperfusion may improve the outcome for patients with AMI.
No takes yet. Share an insight, caveat, or question.
Inagaki et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: